BioVie, Inc. Common Stock
Here’s whether BioVie, Inc. Common Stock (BIVI) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Bearish.
Positives: RSI 51 — healthy momentum range; 3-month momentum positive (+6.9%). Concerns: trading below the 200-day MA (long-term downtrend); below the 50-day MA (medium-term momentum negative); 50-day MA is falling (-0.28% over 10 days); weak 1-year return of -15.7%; rising volume on a downtrend (distribution, 2.92x avg). Currently 63.1% off its 52-week high. Score: -3/7.
BIVI is trading below its 200-day MA ($1.47) — a key warning sign the longer-term trend is under pressure. An RSI of 50.6 sits in the neutral zone — momentum is neither stretched nor exhausted. The 1-year return of -15.7% compares to +20.4% for SPY (trailed the market by 36.0%). The current 63.1% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.